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Abstract
Background: Evidence suggests specialist eating disorders services for children and adolescents with anorexia
nervosa have the potential to improve outcomes and reduce costs through reduced hospital admissions. This study
aimed to evaluate the cost-effectiveness of assessment and diagnosis in community-based specialist child and
adolescent mental health services (CAMHS) compared to generic CAMHS for children and adolescents with
anorexia nervosa.
Method: Observational, surveillance study of children and adolescents aged 8 to 17, in contact with community-
based CAMHS in the UK or Republic of Ireland for a first episode of anorexia nervosa. Data were reported by
clinicians at baseline, 6 and 12-months follow-up. Outcomes included the Children’s Global Assessment Scale
(CGAS) and percentage of median expected body mass for age and sex (%mBMI). Service use data included
paediatric and psychiatric inpatient admissions, outpatient and day-patient attendances. A joint distribution of
incremental mean costs and effects for each group was generated using bootstrapping to explore the probability
that each service is the optimal choice, subject to a range of values a decision-maker might be willing to pay for
outcome improvements. Uncertainty was explored using cost-effectiveness acceptability curves.
Results: Two hundred ninety-eight children and adolescents met inclusion criteria. At 12-month follow-up, there
were no significant differences in total costs or outcomes between specialist eating disorders services and generic
CAMHS. However, adjustment for pre-specified baseline covariates resulted in observed differences favouring
specialist services, due to significantly poorer clinical status of the specialist group at baseline. Cost-effectiveness
analysis using CGAS suggests that the probability of assessment in a specialist service being cost-effective
compared to generic CAMHS ranges from 90 to 50%, dependent on willingness to pay for improvements in
outcome.
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Conclusions: Assessment in a specialist eating disorders service for children and adolescents with anorexia nervosa
may have a higher probability of being cost-effective than assessment in generic CAMHS.
Trial registration: ISRCTN12676087. Date of registration 07/01/2014.
Plain English summary
Specialist eating disorders services may improve outcomes and reduce hospitalisations for children and adolescents
with anorexia nervosa. Reductions in hospitalisation could save money for the NHS and are better for young people
because hospitalisation disrupts their home life, social life and education. This study evaluated outcomes and costs
of specialist eating disorders services compared to general child and adolescent mental health services (CAMHS) for
children and adolescents with anorexia nervosa.
Children and adolescents were identified by contacting child and adolescent psychiatrists in the UK and Ireland and
asking them to report any new cases of anorexia nervosa. These psychiatrists identified 298 young people aged 8
to 17 with an anorexia nervosa diagnosis for the first time. The psychiatrists provided information on the health
services these young people used and how they were doing when they were first diagnosed and 6 months and 1
year later.
Children and adolescents in specialist services were more severely ill than those in CAMHS when they were first
diagnosed. Despite this, care for the young people in specialist services cost about the same as for those diagnosed
in CAMHS, and their outcomes after 1 year were similar. This work showed that specialist services may be better
value for money than CAMHS.
Keywords: Anorexia nervosa, Cost-effectiveness analysis, Specialist eating disorders services, Child and adolescent
mental health services
Background
Anorexia nervosa is an eating disorder associated with
severe physical and psychological impairments and a sig-
nificant cost burden [1–4]. Due to the life-threatening
nature of the disorder, a substantial proportion of chil-
dren and adolescents are admitted to hospital with evi-
dence to suggest that the number of admissions is rising
[5, 6]. Admissions are disruptive to family, school and
social life, costly to health services and relapse rates fol-
lowing inpatient treatment are high [7, 8]. In the United
Kingdom (UK) and Republic of Ireland, children and ad-
olescents with anorexia nervosa are commonly assessed
and diagnosed by generic child and adolescent mental
health services (CAMHS) or specialist community-based
eating disorders services. Few studies have compared the
relative benefits of these different models of care but the
available evidence suggests specialist outpatient treat-
ment may be more effective than generic CAMHS [9,
10]. Economic evidence also supports the case for spe-
cialist services, suggesting that specialist outpatient treat-
ment is cost-effective compared to both inpatient
treatment and generic outpatient treatment [11]. How-
ever, available data are over 10 years old and service
configurations may now be very different. No other eco-
nomic evaluations of specialist eating disorders services
for children and adolescents were identified. A recent
systematic review found only nine economic evaluations
of treatment interventions for all eating disorders in all
ages [12], including the study referred to above [11]. Of
the remainder, seven were carried out in adults or popu-
lations 16 years of age and over and age was unclear in
one study. If the findings from the earlier study [11] can
be shown to be generalisable, investing in specialist eat-
ing disorders services could have significant implications
for the National Health Service (NHS), with the poten-
tial to improve health outcomes and the quality of life of




The Cost-effectiveness of models of care for young
people with Eating Disorders (CostED) study aimed to
evaluate the cost-effectiveness of assessment and diagno-
sis in community-based specialist CAMHS (e.g. specialist
eating disorders services) and generic CAMHS for child
and adolescent anorexia nervosa. The work presented
here is a condensed version of one element of the
CostED study, the full details of which are published
elsewhere [13].
Design
An observational, surveillance study was undertaken
using the Child and Adolescent Psychiatry Surveillance
System (CAPSS), a system designed to identify cases of
rare childhood mental health conditions through
monthly reporting by hospital, community and
university-based child and adolescent psychiatrists in the
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UK and Republic of Ireland [14]. The CostED study in-
volved monthly reporting of new cases of anorexia ner-
vosa for a period of 8 months from 1st February to 30th
September 2015.
Setting
Community-based secondary or tertiary child and ado-
lescent mental health services in the UK and Republic of
Ireland.
Procedures
All CAPSS clinicians were sent a study-specific protocol
card and reporting instructions for new cases of anorexia
nervosa and asked to check boxes to confirm any new
cases of anorexia nervosa seen in the preceding month,
or to check a “nil return” box if appropriate. The proto-
col card detailed the case notification definition for
DSM5 anorexia nervosa [15] (see Appendix) which
aimed to guide clinicians in their decision of whether to
report a positive case. A tear-off slip was provided to en-
able psychiatrists to keep a record of the patients they
reported. Positive returns were allocated a unique CAPS
S ID number by the CAPSS administrator and notified
to the CostED trial manager, who contacted the report-
ing clinician directly to request completion of a baseline
questionnaire.
Participants
Cases were eligible for inclusion if the young person: (1)
was aged 8 to 17 years; (2) had no previous episode of
anorexia nervosa that had come to the attention of ser-
vices; (3) received a clinical assessment in the reporting
service during the study surveillance period; (4) had not
been referred from another secondary health service, to
ensure assessment and diagnosis had not happened prior
to the surveillance period; (5) were notified by a
community-based service; and (6) had the following clin-
ical symptoms reported: “Restriction of energy intake
relative to requirements” and “Persistent behaviour that
interferes with weight gain, despite low weight”. These
two symptoms were used to provide an initial assess-
ment of case eligibility and were subsequently checked
using a tighter DSM5 analytic definition (see Appendix).
Only one case meeting the broad criteria failed to meet
the tighter criteria, thus confirming the validity of the
broad criteria applied. Cases were excluded if the data
were insufficient to assess eligibility.
Data
Data were collected at baseline using questionnaires sent
to clinicians notifying a positive case of anorexia nervosa
and, if the case was found to be eligible for inclusion,
follow-up questionnaires were sent 6 and 12-months
after the date the case was assessed and diagnosed, as
reported by clinicians in the baseline questionnaires. Cli-
nicians completed all questionnaires from clinical
records.
In line with CAPSS procedures and ethics require-
ments, baseline questionnaires contained a limited set of
patient identifiers to describe the sample and identify
duplicate notifications. Patient identifiers included NHS
or Community Health Index number (unique patient
identifiers used in the included regions), hospital num-
ber, first half of postcode or town of residence for Re-
public of Ireland, gender, date of birth and ethnicity
(White, Mixed, Asian, Black, Chinese, Other or Un-
known). In Northern Ireland, identifiers were further
limited to age in years and months (instead of date of
birth) and hospital identifier (instead of hospital num-
ber), to further reduce the risk of patient identification
given the small geographic area. In keeping with the re-
quirements of the Northern Ireland Privacy Advisory
Committee, all patient identifiable data from Northern
Ireland were retained by the local research team, de-
duplicated, anonymised and subsequently sent for ana-
lysis to the central research team in King’s College
London.
The management of duplicates was dependent on the
outcome for the original notification for which a dupli-
cate had been identified. Four scenarios were considered,
and each was assessed in different ways, as follows:
 Duplicates of notifications where the first
notification met the study inclusion criteria, were
excluded and the original notification retained.
 Duplicates of notifications where the first
notification had been excluded due to age (too
young) or clinical ineligibility, were assessed as a
new case to determine if the case now met eligibility
criteria.
 Duplicates of notifications where the first
notification had been excluded due to a previous
episode of anorexia nervosa, an assessment and
diagnosis date prior to the study recruitment period,
or referral from another secondary care service were
excluded.
 Duplicates of notifications where the first
notification contained insufficient information to
judge eligibility for inclusion (for example, missing
date of birth), were checked to see if the second
notification contained the information missing from
the first and, if available, the first notification was
reassessed for eligibility and the duplicate excluded.
Baseline questionnaires covered characteristics of the
notifying service (to enable classification of services as
specialist or generic), clinical characteristics of the noti-
fied case and outcome measures (to assess eligibility and
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provide baseline assessments of outcome), and referral
pathway information (to ensure assessment and diagno-
sis had not happened prior to the surveillance period
and to determine whether the case had been referred to
another service). Follow-up questionnaires included
characteristics of the service, clinical characteristics of
the notified case, outcome measures, and use of health
services.
Incomplete or unreturned questionnaires were pur-
sued via email, post and telephone. Cases where any
symptoms required for case definition remained absent
despite chasing, were assessed for eligibility by a consult-
ant child and adolescent psychiatrist (MS). Those deter-
mined by MS to have too much data missing to assess,
were excluded.
Clinical characteristics and outcome measures
Clinical characteristics included weight and height and a
range of symptoms to support diagnosis (see Appendix).
Weight and height were used to calculate percentage of
median expected body mass index (BMI) for age and sex
(%mBMI) [16, 17]. In addition, clinicians were asked to
report scores for two generic outcome measures: the
Children’s Global Assessment Scale (CGAS) [18] and the
Health of the Nation Outcome Score for Children and
Adolescents (HoNOSCA) [19]. The CGAS is completed
by clinicians and used to rate emotional and behavioural
functioning of young people in the family, school, and
social context. Clinicians score the young person on a
scale from 1 to 100 using a classification which includes
ten categories ranging from ‘Extremely impaired’ (score
1–10) to ‘Doing very well’ (score 91–100) [18]. All
CostED questionnaires contained a copy of the CGAS
classification system, describing each of the ten categor-
ies, to support scoring by clinicians. The HoNOSCA is a
routine outcome measurement tool rating 13 clinical
features on a 5-point severity scale. It assesses behav-
iours, impairments, symptoms, and social functioning of
young people with mental health problems, producing a
total score on a scale from 0 to 52, where a higher score
indicates a poorer outcome.
Although there is a preference for generic measures of
health-related quality of life capable of generating quality
adjusted life years (QALYs) in economic evaluations –
since this allows for comparison across populations and
disorders when making resource allocation decisions –
no such measure is routinely collected by NHS clinical
services. Given the reliance on data from clinical re-
cords, it was therefore not possible to undertake a cost-
utility analysis, which uses QALYs as the measure of ef-
fect, as is preferred, for example, by the National Insti-
tute for Health and Care Excellence which produces
clinical guidelines in England [20].
Service use and costs
Since data were collected from clinical records, the per-
spective of the economic evaluation was limited to
health services for which data were likely to be available
to clinicians. This included: hospital inpatient admis-
sions (including paediatric, general child/adolescent or
adult psychiatry, child/adolescent or adult eating disor-
ders unit, or other), out-patient attendances (including
paediatrics, specialist eating disorders service, and other
psychiatric service) and day-patient attendances (includ-
ing paediatrics, specialist eating disorders service, and
other psychiatric service). Adult services were included
because some adolescents may have transferred to adult
services by follow-up.
All costs, in pounds sterling, were for the 2015/16 fi-
nancial year, in line with the data collection period. Dis-
counting was not necessary as follow-up was not longer
than 12-months. Costs for NHS hospital admissions and
outpatient and day-patient contacts, including CAMHS
contacts, were taken from NHS reference costs [21]. In-
dependent sector costs were provided by a range of in-
dependent sector organisations and NHS Trusts via
personal communications. Unit costs are summarised in
Table 1.
Classification of services
Specialist eating disorders services are not clearly de-
fined, with definitions changing over time [22, 23]. In
order to classify services as specialist or generic, an on-
line Delphi survey was undertaken to obtain consensus
on the key features of a specialist child and adolescent
eating disorders service from a range of stakeholders, in-
cluding service users and their families, child and adoles-
cent psychiatrists, paediatricians, other eating disorders
professionals and service commissioners [13]. Further
information regarding the characteristics included in the
Delphi survey can be found in the published report [13].
Characteristics meeting pre-defined consensus thresh-
olds to be considered important for the classification of
services as specialist eating disorders services included:
offering specialist outpatient treatment for eating disor-
ders, providing multi-disciplinary specialist outpatient
clinics dedicated to eating disorders and holding weekly
multi-disciplinary meetings dedicated to eating disor-
ders. All cases notified by a service meeting all three cri-
teria were classified as specialist; all other services were
classified as generic CAMHS.
Data analysis
Analyses compared participants assessed in specialist
eating disorders services with those assessed in generic
CAMHS. All analyses were adjusted for pre-specified
baseline covariates including CGAS, %mBMI, age, sex
and region (England, Wales, Scotland, Northern Ireland,
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Republic of Ireland). Outcomes and total costs per par-
ticipant were compared using standard parametric t-
tests [24], with the robustness of this approach for costs
confirmed using bootstrapping (5000 iterations) [25].
Analyses used complete case data with the impact of
missing cost and outcome data over the follow-up
period tested in sensitivity analyses using multiple impu-
tations [26]. Alternative approaches to the handling of
observational data were considered, such as matching
and stratification [27], but small sample sizes, com-
pounded by missing data at baseline and follow-up, and
imbalance in the size of the two groups (specialist versus
generic) precluded these, and more sophisticated,
approaches.
The pre-specified primary measure of effectiveness,
as outlined in the original protocol, was the HoN-
OSCA. The %mBMI was specified as a secondary
cost-effectiveness analysis because, although more
narrowly focused, data on weight and height were ex-
pected to be available for a greater proportion of the
sample. From the baseline questionnaires, however,
the level of missing HoNOSCA data was substantial
(79% missing at baseline) and the protocol was
amended replacing the HoNOSCA with the CGAS,
for which a greater proportion of data were available
(8% missing at baseline).
Cost-effectiveness was explored in a decision-
making context, focusing on the probability of one
service type being cost-effective compared to the
other, given the data available, rather than a focus on
statistical significance. This is the recommended ap-
proach for economic evaluation in the UK [28]. Cost-
effectiveness was assessed using incremental cost-
effectiveness ratios (difference in mean cost between
two interventions divided by the difference in mean
effect) and taking the recommended net benefit ap-
proach [29]. Incremental cost-effectiveness ratios were
calculated for scenarios where one intervention dem-
onstrates higher costs and better outcomes (it is un-
necessary to calculate these ratios where one group
shows both lower costs and better outcomes as it
‘dominates’ the other group). A joint distribution of
incremental mean costs and effects for each group
was generated using bootstrapping [25] to explore the
probability that each service is the optimal choice,
subject to a range of values a decision-maker might
be willing to pay for outcome improvements (£0 to
£30,000). Cost-effectiveness acceptability curves were
generated by plotting these probabilities for a range
of possible values of the ceiling ratio [30, 31]. These
curves are the recommended approach to dealing
with uncertainty around the cost and effect estimates
Table 1 Unit costs for health services used
Service Unit cost Source
NHS inpatient cost per night
Eating disorders unit – child/adolescent 510.14 NHS Reference Costsa
Eating disorders unit – adult 455.02 NHS Reference Costsa
General psychiatry – child/adolescent 633.07 NHS Reference Costsa
General psychiatry – adult 197.29 NHS Reference Costsa
Paediatric if stay = 1 night 426.99 NHS Reference Costsa
Paediatric if stay> 1 night 592.27 NHS Reference Costsa
Other NHS 389.10 NHS Reference Costsa
Independent sector inpatient cost per night
Eating disorders unit – child/adolescent 695.00 Personal communication
General psychiatry – child/adolescent 668.00 Personal communication
Outpatient cost per contact
Eating disorders service 262.12 NHS Reference Costsa
Other psychiatry 298.57 NHS Reference Costsa
Paediatric 194.36 NHS Reference Costsa
Day-patient cost per contact
Eating disorders service 274.21 NHS Reference Costsa
Other psychiatry 326.16 NHS Reference Costsa
Paediatric 446.60 NHS Reference Costsa
aDepartment of Health. NHS reference costs. 2015
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and the maximum cost-effectiveness ratio that
decision-maker would consider acceptable [28, 31].
Results
Sample
Over the eight-month surveillance period, 6401 case no-
tification cards were sent to clinicians and 3211 were
returned (50.16%). Of these, 997 positive cases of an-
orexia nervosa were reported and 2214 were nil returns.
Of the 997 positive returns, 48 (5%) were excluded due
to reporting errors or clinicans stating that they did not
wish to take part in the study (due to lack of time, retire-
ment etc.). Baseline questionnaires were sent to clini-
cians who reported the remaining 949 positive returns,
and 597 (63%) were returned. Of these, 299 (49%) were
ineligible (due to age, previous episode of anorexia ner-
vosa, date of assessment outside the surveillance period,
referral from another secondary care service, current in-
patient, duplicate notification or insufficient information
to assess diagnosis). Thus 298 cases were included in the
study, 192 (64%) assessed in a specialist eating disorders
service and 106 (36%) assessed in generic CAMHS. Cli-
nicians completed and returned follow-up question-
naires for 220 cases at 6-months (74%), 147 specialist
(77%) and 73 generic (69%), and 187 cases at 12-months
(63%), 137 specialist (71%) and 50 generic (47%). In-
cluded cases were referred from a total of 79 services, 50
of which were generic CAMHS (63%) and 29 were spe-
cialist eating disorders services (37%).
Demographic and baseline characteristics are reported
in Table 2. Mean age (approx. 15 years), proportion fe-
male (92%) and ethnicity (92–94% Any White back-
ground) were similar between the two groups and in line
with evidence of the demographic at risk for anorexia
nervosa [32]. Baseline clinical variables suggest the sam-
ple were significantly impaired. Mean %mBMI was ap-
proximately 83%, falling within the range expected for a
diagnosis of anorexia nervosa (< 85%). Mean CGAS
score was approximately 44, falling within the ‘obvious
problems’ range [18], and mean total HoNOSCA score
was approximately 19, indicative of a severity similar to
that at inpatient admission [9, 33]. Comparing the two
groups, %mBMI was similar in the two groups (82.7%
versus 83.6%) but differences were evident for CGAS
(mean 43 specialist versus 48 generic) and HoNOSCA
(mean 21 specialist versus 15 generic).
Service use
Mean use of inpatient, outpatient and day-patient ser-
vices over the 12-month follow-up is reported in Table 3.
Mean number of inpatient admissions and inpatient
nights per participant were similar in the two groups, al-
though participants assessed in specialist services spent
longer, on average, in eating disorders facilities (20 ver-
sus 13 nights) and less time on general psychiatry wards
(7 versus 13 nights). The pattern for outpatient atten-
dances was similar, with participants assessed in special-
ist services having more contacts in eating disorders
facilities (27 versus 15 attendances) but fewer general
psychiatry contacts (3 versus 12 attendances) and a simi-
lar number of contacts in total (30 versus 27 atten-
dances). Day-patient services were accessed by 11% of
the specialist group but only 4% of the generic group,
with average number of attendances also being higher
for the specialist group (5 versus 1 attendance). Most of
these contacts were in eating disorders services.
Cost
Cost results are reported in Table 4. Although there were
only small observed differences in total costs, adjustment
for pre-specified baseline variables made a substantial dif-
ference due to baseline differences, particularly in the
CGAS. Adjusted analyses suggested large differences in
favour of specialist services (costs lower on average), al-
though these differences were not significant. Imputation
of missing data made little difference to the results, with
costs remaining lower in the specialist group in adjusted
analyses.
Outcomes
Outcome results are reported in Table 5. At baseline,
%mBMI was not statistically different between the
two groups. However, both CGAS and HoNOSCA
scores were significantly worse in the specialist group.
At the 6-month follow-up, in adjusted analyses,
%mBMI was significantly higher in the specialist than
the generic group. Although %mBMI remained higher
for the specialist group at 12-months, the difference







Age 192 15.09 (1.60) 106 14.84 (1.66)
Sex
Female 176 91.67% 97 91.51%
Male 16 8.33% 9 8.49%
Ethnicity
Any White 174 91.58% 95 94.06%
Other 16 8.42% 6 5.94%
Clinical status
%mBMI 191 82.70 (11.11) 105 83.60 (9.90)
CGAS 174 43.22 (14.40) 99 47.86 (13.29)
HoNOSCA 45 21.04 (8.43) 16 14.88 (5.77)
NB: Not all percentages add up to 100% due to rounding
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was no longer significant. No significant differences
were identified for CGAS or HoNOSCA at either
follow-up. Imputation of missing data made little dif-
ference, with imputed results being similar to
complete case results.
Cost-effectiveness
Using the CGAS (primary measure of effect) at 12-
months (primary endpoint), adjusted total costs per par-
ticipant were lower and adjusted CGAS scores slightly
lower (poorer outcomes) in the specialist than the





Service Mean (SD) % using Mean (SD) % using
Inpatient admissions 0.54 (1.06) 28.47% 0.60 (1.20) 30.00%
Inpatient nights 31.75 (80.03) 28.47% 30.78 (68.65) 30.00%
Paediatric – NHS 2.18 (9.28) 15.33% 4.72 (12.96) 20.00%
Eating disorders – NHS 5.56 (37.72) 2.92% 0.28 (1.98) 2.00%
Eating disorders – Independent 14.28 (57.93) 8.76% 12.84 (49.89) 8.00%
Psychiatry – NHS 5.38 (24.47) 6.57% 11.58 (39.42) 12.00%
Psychiatry – Independent 1.39 (12.43) 2.19% 1.36 (9.62) 2.00%
Other – NHS 0.53 (6.15) 1.46% 0.00 (0.00) 0.00%
Outpatient attendances 29.98 (17.70) 98.54% 27.14 (32.62) 96.00%
Paediatric 0.07 (0.34) 5.11% 0.98 (2.46) 28.00%
Eating disorders 27.11 (18.11) 92.70% 14.58 (32.07) 56.00%
Psychiatry 2.80 (8.94) 17.52% 11.58 (13.55) 68.00%
Day patient attendances 4.61 (16.60) 10.95% 0.86 (5.66) 4.00%
Paediatric 0.00 (0.00) 0.00% 0.06 (0.42) 2.00%
Eating disorders 4.25 (16.13) 10.22% 0.80 (5.66) 2.00%
Psychiatry 0.37 (4.27) 0.73% 0.00 (0.00) 0.00%
Table 4 Total cost per participant between baseline and 12-month follow-up
Specialist Generic Unadjusteda Adjustedab





Baseline to 6 months n = 147 n = 73
Inpatient 11105 (28877) 11179 (29050)
Outpatient 4764 (2866) 4310 (3975)
Day-patient 947 (3468) 299 (1708)
Total 16817 (28469) 15789 (28184) 1028 (− 6979 to 9036) 0.801 − 3586 (−11999 to 4827) 0.402
Six to 12months n = 137 n = 50
Inpatient 8153 (24763) 8224 (20894)
Outpatient 3103 (3058) 3279 (5775)
Day-patient 306 (1703) 44 (310)
Total 11562 (24905) 11547 (22133) 14 (− 7875 to 7903) 0.997 − 2785 (− 11241 to 5670) 0.516
Baseline to 12months n = 137 n = 50
Inpatient 19462 (49946) 19755 (44677)
Outpatient 7955 (4722) 7470 (8499)
Day-patient 1284 (4608) 246 (1559)
Total 28700 (49716) 27471 (44317) 1230 (−14529 to 16988) 0.878 −7106 (−23590 to 9379) 0.396
NB: Not all totals add up due to rounding; aStandard parametric tests with validity tested using bootstrapping (bootstrapped results similar so not reported);
bAdjusted for baseline CGAS, baseline %mBMI, age, sex and region
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generic group, generating an incremental cost-
effectiveness ratio of £10,932 (−£7106/− 0.65). This sug-
gests that assessment in a generic service generates a
unit improvement in CGAS score for an additional cost
of approximately £11,000, compared to specialist ser-
vices. The cost-effectiveness plane in Fig. 1 illustrates
that the scatter points fall in all four quadrants, but the
largest proportion are in the South-West quadrant
where specialist services are cheaper (below the x-axis)
and less effective (left of the y-axis). At the 6-month
follow-up, adjusted total costs per participant were lower
in the specialist group and adjusted CGAS scores slightly
higher (better outcomes), so specialist services domi-
nated generic services (Fig. 2).
Cost-effectiveness acceptability curves (Fig. 3), are
downward sloping, suggesting that the cost-effectiveness
of specialist eating disorders services declines as willing-
ness to pay for improvements in CGAS increase, but
Table 5 Outcome measures at baseline, 6 and 12-month follow-up
Specialist Generic Unadjusteda Adjustedab






%mBMI 191 82.70 (11.10) 105 83.60 (9.90) −0.90 (−3.46 to 1.66) 0.489
CGAS 174 43.22 (14.40) 99 47.86 (13.29) −4.64 (−8.11 to −1.17) 0.009
HoNOSCA 45 21.04 (8.43) 16 14.88 (5.77) 6.17 (1.60 to 10.74) 0.009
6-months
%mBMI 143 91.98 (8.51) 67 89.62 (12.89) 2.37 (−0.59 to 5.31) 0.116 2.58 (0.16 to 5.01) 0.037
CGAS 115 58.94 (17.17) 55 63.27 (17.05) −4.33 (−9.88 to 1.21) 0.125 0.49 (−5.14 to 6.12) 0.864
HoNOSCA 17 9.47 (7.43) 16 11.88 (10.31) −2.40 (−8.76 to 3.95) 0.446 −6.61 (−15.54 to 2.31) 0.140
12-months
%mBMI 106 94.70 (10.61) 39 93.36 (9.46) 1.34 (−2.48 to 5.16) 0.489 0.09 (−3.54 to 3.73) 0.960
CGAS 97 68.39 (17.95) 38 71.58 (21.41) −3.19 (−10.37 to 4.00) 0.382 −0.65 (−8.26 to 6.96) 0.866
HoNOSCA 12 7.42 (4.48) 7 13.57 (16.94) −6.15 (−16.88 to 4.57) 0.243 −12.42 (−31.07 to 6.23) 0.171
aStandard parametric tests; bAdjusted for baseline CGAS, baseline %mBMI, age, sex and region; %mBMI percentage of median expected BMI for age and sex
(higher percentage, better outcome), CGAS Children’s Global Assessment Scale (scored between 1 and 100; higher score, better outcome), HoNOSCA Health of the
Nation Outcome Score for Children and Adolescents (scored between 0 and 52; higher score, poorer outcome)
Fig. 1 Cost-effectiveness plane for CGAS at 12-months
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does not fall below 50% over the willingness to pay range
tested. This is due to the lower cost of the specialist
group and the small differences in effects (i.e., at low
levels of willingness to pay, society favours the cheaper
option, but at higher levels of willingness to pay, society
becomes increasingly indifferent between the two op-
tions). The curves illustrate that there is a higher prob-
ability of assessment in specialist services being cost-
effective compared to generic services at both follow-
ups, with probabilities at 12-months ranging from
around 90% at zero willingness to pay for improvements
in CGAS to 50% at willingness to pay of £30,000.
In terms of %mBMI, the secondary measure of effect,
adjusted total costs per participant were lower and
%mBMI scores were slightly higher (better outcome) in
the specialist than the generic group at both the 6-
Fig. 2 Cost-effectiveness plane for CGAS at 6-months
Fig. 3 Cost-effectiveness acceptability curves for CGAS at 6 and 12-months
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month and 12-month follow-ups, so specialist services
dominated generic services (Figs. 4 and 5). Cost-
effectiveness acceptability curves (Fig. 6) suggest there is
a higher probability of initial assessment in specialist ser-
vices being cost-effective compared to generic services at
both follow-ups, with probabilities at 12-months ranging
from 76% at zero willingness to pay to 56% at willing-
ness to pay of £30,000.
Discussion
Overview of the results
The results presented suggest that for children and ado-
lescents aged 8 to 17 with anorexia nervosa in the UK
and Republic of Ireland, assessment in specialist eating
disorders services has a similar or higher probability of
being cost-effective than assessment in generic CAMHS.
At 12-months follow-up, specialist eating disorders
Fig. 4 Cost-effectiveness plane for %mBMI at 12-months
Fig. 5 Cost-effectiveness plane for %mBMI at 6-months
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services had a higher probability of being cost-effective
than generic CAMHS at low levels of willingness to pay
for improvements in CGAS score and improvements in
%mBMI; at higher levels of willingness to pay, the prob-
ability of either specialist or generic being cost-effective
was around 50%. At 6-months follow-up, assessment in
specialist eating disorders services had a higher probabil-
ity of being cost-effective for the full range of willingness
to pay values tested (£0 to £30,000). Without knowledge
of the amount society is willing to pay for improvements
in CGAS or %mBMI, no firm conclusions can be
reached. However, we would hypothesise that it is un-
likely that decision-makers would be willing to pay in
excess of £30,000 for a one percentage point improve-
ment in either measure, which is the minimum amount
that would need to be spent for generic CAMHS to have
a similar or higher probability of being cost-effective
compared to specialist services.
Cost-effectiveness findings in favour of specialist
services were due to similar outcomes in the two
groups alongside lower costs in the specialist group,
following adjustment for poorer baseline clinical sta-
tus in the specialist group. Despite this poorer base-
line status, children and adolescents assessed in
specialist services achieved significantly better weight
outcomes 6-months after assessment and similar out-
comes at 12-months compare to those assessed in
generic CAMHS, with a similar level of health service
use, and thus similar costs.
These results are in line with previous evidence to
support the cost-effectiveness of specialist services for
children and adolescents with anorexia nervosa. One
RCT carried out in the UK, concluded that specialist
out-patient treatment has a higher probability of being
cost-effective than inpatient or general outpatient treat-
ment [9, 11]. In common with the CostED study, there
were no differences in outcomes, however the specialist
outpatient group had substantially lower costs than the
comparison groups over two-year follow-up. Similar re-
sults were seen in a London-based study [34]. Whilst no
significant differences in outcome were evident, admis-
sions were significantly lower over one-year follow-up
for children and adolescents assessed and treated in a
specialist service (15% admitted) compared with those
assessed and treated in a non-specialist service (40%).
From a pragmatic point of view, combining the CostED
study results with previous evidence to support the cost-
effectiveness of specialist community-based services [11]
and to suggest that specialist services reduce admissions
and costs [34], the evidence as a whole supports the
provision of specialist eating disorders services, which is in
line with recent guidance for and investment into the de-
velopment of community eating disorders services for
children and adolescents in England [22]. In addition, the
CostED results should be considered alongside other fac-
tors of relevance to investment decisions, in particular the
preferences of patients and carers. Existing evidence sug-
gests a preference from these groups for specialist services
[34–36], making the differential use of inpatient and out-
patient services identified – with children and adolescents
assessed in specialist services having greater contact with
eating disorders facilities and less contact with general
psychiatry services than those assessed in generic services
– of particular importance.
Fig. 6 Cost-effectiveness acceptability curve for %mBMI at 6 and 12-months
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Strengths and limitations
Anorexia nervosa is a relatively rare disorder, in com-
parison to other childhood mental health disorders, such
as depression, making it difficult to recruit adequately
powered samples for clinical trials. This surveillance
study was able to gather case notifications from almost
one hundred services across the UK and Republic of
Ireland, which for a clinical trial would be prohibitively
expensive. After accounting for duplicates and with-
drawals, 298 cases were eligible for inclusion, a sample
which is larger than RCTs in this population have been
able to achieve to date [9, 37, 38]. However, it should be
noted that this sample does not reflect the entire popu-
lation of children and adolescents with an anorexia ner-
vosa diagnosis for the first time in this age range, as only
50% of case notification cards were returned. Whilst a
proportion of these would have been ‘nil’ returns (no
case of anorexia nervosa to report), some will have been
missing cases of anorexia nervosa meeting the study in-
clusion criteria.
In addition, the study benefits from being ‘real world’,
reflecting actual clinical practice with standard clinical
populations, broad inclusion criteria and limited exclusion
criteria. However, the results were clearly affected by base-
line differences in outcome scores between the two
groups, which is a limitation of evaluations that do not
randomly allocate participants, and may also reflect a level
of participant self-selection, at least in those participants
with access to both types of services. All analyses were
therefore adjusted for baseline variables to minimise the
impact of this limitation. Alternative approaches to the
handling of observational data were considered, but small
sample sizes, missing data, and imbalance in the size of
the two groups precluded such approaches and thus the
results should be interpreted within the context of the
methodological limitations of the study.
At baseline, 63% of questionnaires were returned allowing
cases to be assessed for eligibility for inclusion in the
follow-up. Of those assessed as eligible, 74% of 6-month
follow-up questionnaires and 63% of 12-month follow-up
questionnaires were returned. Missing data was therefore a
limitation which impacts upon the generalisability and in-
terpretation of the results. However, imputation of missing
data produced very similar results to complete case ana-
lyses, giving greater confidence in the results presented. In
contrast, missing items in returned questionnaires were
small in number, except for the HoNOSCA, suggesting that
clinical services are not using this measure in routine prac-
tice. As a result, the HoNOSCA was removed as the pre-
specified primary outcome measure and replaced with the
CGAS, which had substantially higher response rates.
Some limitations arose directly from reliance on retro-
spective data contained within clinical records, rather than
prospective collection from children and adolescents. In
particular, availability of outcome data was limited to
CGAS scores and %mBMI. These outcomes are too nar-
row to capture all impacts clinical services may have on
the quality of life of children and adolescents with an-
orexia nervosa which suggests the need for clinical ser-
vices to consider the consistent collection of measures of
change, including measures relevant to eating disorders
and broader measures of quality of life, to aid investigation
of the effectiveness of services from both a clinical and a
research point of view. Similarly, service use was limited
to those health services for which data were likely to be
available to all clinicians from clinical records, although
this did capture the key services found in previous evalua-
tions to account for the vast majority (over 90%) of the
total costs in similar samples [11, 34]. Adjustment for con-
founding factors was also limited by the availability of data
in clinical records, and thus it is possible that unobserved
factors of importance were missed.
Whilst recruitment from across the UK and Repub-
lic of Ireland avoids biases inherent in studying clin-
ical samples from a small number of services across a
narrow range of geographical locations, bias in report-
ing and questionnaire completion is likely to be a
problem. Specialist services have larger numbers of
eating disorders cases than generic CAMHS, placing a
greater questionnaire completion burden on clinicians,
which may reduce their willingness to respond. How-
ever, those in specialist services are more likely to
have an interest in the research, which may have a
positive effect on their willingness to take part. Whilst
the direction of any bias at the reporting stage is un-
known, it is worth noting that a much larger propor-
tion of the total number of services reporting at least
one notification were generic CAMHS (over 60%),
suggesting that these services were engaging with the
study. However, biases in questionnaire completion at
follow-up were evident, with completion rates being
higher in the specialist group (77% at 6-months; 71%
at 12-months follow-up) compared to generic CAMH
S (69% at 6-months; 47% at 12-months follow-up).
The CostED study was also open to bias from loss to
follow-up due to referral elsewhere or discharge – likely
to be a particular problem as adolescents reach 18 years
of age and move to university or to take up employment.
Follow-up data were less likely to be available for partici-
pants who were doing well and had been discharged
prior to follow-up, for participants who were doing badly
and had been admitted to hospital or referred from gen-
eric CAMHS to specialist services, and for participants
who had moved out of area. Although the small differ-
ences in outcomes between the groups may suggest that
loss to follow-up due to discharge may also be similar,
evidence that children and adolescents treated in generic
services are supported for longer than those in specialist
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services [34] would suggest that loss of data due to dis-
charge may have been greater for specialist services.
In terms of loss of data due to hospital admission, spe-
cialist services will generally remain in regular contact
with their patients while they are in hospital and will
also continue outpatient treatment following discharge.
Although practice is variable, this is less likely to be the
case in generic services, so data loss as a result of referral
may have been greater in generic services. It is also
worth noting that there was considerably greater loss to
follow-up in generic services, particularly at 12-months
(53% versus 29%), and if this indicates a greater propor-
tion of participants doing badly who are admitted to
hospital or referred to specialist community services, this
would have biased the results in favour of generic
CAMHS. This type of loss to follow-up may also explain
the surprisingly low lengths of admissions in the CostED
sample compared to other studies [34, 39].
A further bias may arise from the exclusion of children
and adolescents admitted directly to inpatient facilities
without any contact with community-based services,
which may be more likely in areas where community-
based specialist eating disorders services are not avail-
able. This potentially introduces a bias in favour of gen-
eric CAMHS since these children and adolescents will
be receiving considerably more expensive care as inpa-
tients than the cost of treating them in community-
based generic services would have been. Finally, it
should be noted that nationally applicable unit costs
were applied to most services, which increases the gen-
eralisability of the results to the national picture but re-
duces variability and the local applicability of the results.
Conclusion
Assessment and diagnosis in a specialist eating disorders
service for children and adolescents with anorexia ner-
vosa may have a higher probability of being cost-
effective than assessment and diagnosis in generic
CAMHS, as specialist services were able to achieve lar-




Please report any child/young person aged 8 to 17 years
and 11 months inclusive, who meets the case notification
definition criteria below for the first time in the last
month. One bullet point criterion from each group
below should be fulfilled.
Group A
 Restriction of food, low body weight, or
 Weight less than expected for age
Group B
 Fear of gaining weight, or
 Fear of becoming fat, or
 Behaviour that interferes with weight gain, for
example excessive exercising, self-induced vomiting,
use of laxatives and diuretics
Group C
 Body image disturbance, or
 Persistent lack of recognition of the seriousness of
the current low body weight
Exclusions
 Patients who are not underweight
 Patients with bulimia nervosa, binge eating disorder,
avoidant restrictive food intake disorder or other
failure to thrive presentations
DSM5 analytic definition
The tighter DSM5 analytic definition used to check the
validity of the broad ‘two-symptom’ definition, included
the following symptoms:
1. “Restriction of energy intake relative to
requirements” and
2. “Intense fear of gaining weight or of becoming fat”
or “Persistent behaviour that interferes with weight
gain, despite low weight” and
3. “Perception that body shape/size is larger than it is”
or “Preoccupation with body weight and shape” or
“Lack of recognition of the seriousness of the
current low body weight”
Clinical symptoms contained in the CostED
questionnaires to support DSM5 diagnosis
Clinical symptoms included in the baseline, 6 and 12-
month follow-up questionnaires were used to support
diagnosis of DSM5 anorexia nervosa and included the
following features which required a response of yes, no,
not known or not applicable: restriction of energy intake
relative to requirements; intense fear of gaining weight
or of becoming fat; persistent behaviour that interferes
with weight gain, despite low weight; perception that
body shape/size is larger than it is; preoccupation with
body weight and shape; lack of recognition of the ser-
iousness of the current low body weight; excessive exer-
cise; self-induced vomiting (including frequency);
laxative or diuretic abuse; and binge eating (including
frequency). In addition, for females, clinicians were
asked if the young person had reached menarche and, if
yes, whether there was secondary amenorrhoea.
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